Linvoseltamab in Combination for Multiple Myeloma
This study is testing a new drug called linvoseltamab in combination with other cancer treatments (daratumumab, carfilzomib, lenalidomide, or bortezomib) for adults with multiple myeloma. Multiple myeloma is a blood cancer that has become resistant to standard treatments. Linvoseltamab has shown promise in previous studies as a single treatment, with some patients experiencing complete responses (no evidence of cancer). This trial is the first time linvoseltamab will be combined with other therapies. The main goal is to find out if these combinations are safe and what dose of linvoseltamab works best with each treatment. You might be able to join if you are 18 or older, have measurable disease, and good overall health.
- Study design
- This interventional study plans to enroll 317 participants. The phase of the study is not specified, and its current status is unclear.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for treatment-emergent adverse events (side effects) for up to 5 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
At a glance
Conditions
Where it's being run
42 sites across 26 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation periodUp to 28 Days
Dose finding portion only
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Up to 5 Years
- Severity of TEAEsUp to 5 Years
- Incidence of Serious Adverse Events (SAEs)Up to 5 Years
- Severity of SAEsUp to 5 Years
- Incidence of Adverse Events of Special Interest (AESIs)Up to 5 Years
- Severity of AESIsUp to 5 Years
- Incidence of laboratory abnormalitiesUp to 5 Years
≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE v5.0\]